Advanced search
Publication Cover
Expert Opinion on Emerging Drugs Volume 8, 2003 - Issue 1
Submit an article Journal homepage
171
Views
18
CrossRef citations to date
0
Altmetric
Review

Treatments for stroke

Isabel JM Beresford Neurology & GI Centre of Excellence for Drug Discovery, GlaxoSmithKline Research & Development Ltd, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW, UK
,
Andrew A Parsons Neurology & GI Centre of Excellence for Drug Discovery, GlaxoSmithKline Research & Development Ltd, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW, UK
&
A Jacqueline Hunter Neurology & GI Centre of Excellence for Drug Discovery, GlaxoSmithKline Research & Development Ltd, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW, UK
Pages 103-122 | Published online: 02 Mar 2005

Bibliography

  • ROSAMOND WD, FOLSOM AR, CHAMBLESS LI et al.: Stroke incidence and survival among middle-aged adults. Stroke (1999) 30:736–743.
  • MURRAY CJL, LOPEZ AD: Mortality by cause for eight regions of the world: global burden of disease study. Lancet (1997) 349:1269–1276.
  • WILLIAMS GR, JIANG JG, MATCHAR DB, SAMSA GP: The incidence and occurrence of total (first-ever and recurrent) stroke. Stroke (2000) 31:2523–2528.
  • HANKEY GJ, WARLOW CP: Treatmentand secondary prevention of stroke: evidence, costs, and effects on individuals and populations. Lancet (1999) 354:1457–1463.
  • TAYLOR TN, DAVIS PH, TORNER JC,HOLMES J, MEYER JW, JACOBSON MF: Lifetime cost of stroke in the United States. Stroke (1996) 27:1459–1466.
  • HACKE W, BROTT T, CAPLAN LR et al.: Thrombolysis in acute ischemic stroke: controlled trials and clinical experience. Neurology (1999) 53(Suppl.):S3–S14.
  • KIDWELL CS, LIEBESKIND DS, STARKMAN S, SAVER JL: Trends in acute ischemic stroke trials through the 20th century. Stroke (2001) 32:1349–1359.
  • SCHELLINGER PD, FIEBACH JB, MOHR A, RINGLEB MD, JANSEN O, HACKE W: Thrombolytic therapy for ischemic stroke - a review. Part I - intravenous thrombolysis. Crit. Care Med. (2001) 29:1812–1818.
  • •Comprehensive review of clinical trials of intravenous thrombolytic therapy for acute stroke.
  • CLARK WM, WISSMAN S, ALBERS GW, JHAMANDAS JH, MADDEN KP, HAMILTON S: Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS study: a randomized controlled trial. Alteplase thrombolysis for acute noninterventional therapy in ischemic stroke. JAMA (1999) 282:2019–2126.
  • BRAVATA DM, KIM N, CONCATO J et al.: Thrombolysis for acute stroke in routine clinical practice. Arch. Int. Med. (2002) 162:1994–2001.
  • CHEN ZM, COLLINS R, LIU LS, PAN HC, PETO R: CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet (1997) 349:1641–1649.
  • ALBERS GW, EASTON JD, SACCO RL,TEAL P: Antithrombotic and thrombolytic therapy for ischemic stroke. Chest (1998) 114:S683–S698.
  • •Comprehensive review of clinical trials of antithrombotic and thrombolytic therapies for stroke.
  • SANDERCOCK P, COLLINS R, COUNSELL C et al: The international stroke trial (1ST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet (1997) 349:1569–1581.
  • •Clinical trial which demonstrates that aspirin, but not heparin, has some efficacy for treatment of acute stroke.
  • BATH PMW, IDDENDEN R, BATH FJ: Low molecular-weight heparins and heparinoids in acute ischemic stroke. Stroke (2000) 31:1770–1778.
  • •Meta-analysis of clinical trials which demonstrates lack of efficacy of low molecular-weight heparins for acute stroke.
  • MCGUIRE JR, HARVEY RL: The prevention and management of complications after stroke. Phys. Med. Rehabil Clin. North Ain. (1999) 10:857–874.
  • GELBER DA, GOOD DC, DROMERICK A, SERGAY S, RICHARDSON M: Open-label dose-titration safety and efficacy study of tizanidine hydrochloride in the treatment of spasticity associated with chronic stroke. Stroke (2001) 32:1841–1846.
  • BRASHEAR A, GORDON ME ELOVIC E et al.: Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl. Med. (2002) 347:395–400.
  • ROMAN GC: Vascular dementia revisited:diagnosis, pathogenesis, treatment and prevention. Med. Clin. North Ain. (2002) 86:477–499.
  • •Comprehensive review of emerging treatments of vascular dementia.
  • FLICKER L, GRIMLEY EVANS J: Piracetam for dementia or cognitive impairment. Cochraine Database Syst. Rev (2001) 2:CD001011.
  • CACEBELOS R, ALVAREZ XA, FRANCO-MASIDE A et al.: Effect of CDP-choline on cognition and immune function in Alzheimer's disease and multi-infarct dementia. Ann. NY Acad. Sci. (1993) 695:321–323.
  • MOBIUS HJ, STOFFLER A: Pharmacologic rationale for memantine in chronic cerebral hypoperfusion, especially vascular dementia. Alzheimer Dis. Assoc. Disord. (1999) 13\(Suppl. 3):5172–5178.
  • GORELICK PB: Stroke prevention - windows of opportunity and failed expectations - a discussion of modifiable cardiovascular risk factors and a prevention proposal. Neuroepidennol (1997) 16:163–173.
  • BOSCH J, YUSUF S, POGUE J et al: Use of ramipril in preventing stroke: double blind randomised trial. Br. Med. Bull. (2002) 324:699–703.
  • GORELICK PB: New horizons for stroke prevention: PROGRESS and HOPE. Lancet Neurol (2002) 1:149–156.
  • DE FREITAS GR, BOGOUSSLAVSKY J: Primary stroke prevention. Eur. Neurol (2001) 8:1–15.
  • ••Reviews stroke risk factors and strokeprevention clinical trials.
  • COLLINS R, PETO R, BAIGENT C et al: Collaborative overview of randomised trials of antiplatelet therapy. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br. Med. (1994) 308:81–106.
  • STEPHENSON J: Rising stroke rates spur efforts to indentify risks, prevent disease. JAMA (1998) 279:1239–1240.
  • DIRNAGL U, IADECOLA C, MOSKOWITZ MA: Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. (1999) 22:391–397.
  • ••Good overview of the ischaemic cascade.
  • FRIJNS CJM, KAPPELLE LJ: Inflammatory cell adhesion molecules in ischemic cerebrovascular disease. Stroke (2002) 33:2115–2122.
  • •Review of the role of cell adhesion molecules in cerebral ischaemia.
  • STOLL G, JANDER S, SCHROETER M: Inflammation and glial responses in ischemic brain lesions. Frog. Neurobiol (1998) 56:149–171.
  • •Review of the inflammatory response following focal cerebral ischaemia.
  • SKILBECK CE, WADE DT, HEWER RL,WOOD VA: Recovery after stroke. Neural. Neurosurg. Psych. (1983) 46:5–8.
  • KOTILA M, WALTIMO O, NIEMI ML, LAAKSONEN R, LEMPINEN M: The profile of recovery from stroke and factors influencing outcome. Stroke (1984) 15:1039–1044.
  • STROEMER RP, KENT TA, HULSEBOSCH CE: Neocortical neural sprouting, synaptogenesis and behavioural recovery after neocortical infarction in rats. Stroke (1995) 26:2135–2144.
  • KAWAMATA T, DIETRICH WD, SCHALLERT T et al.: Intracisternal basic fibroblast growth factor enhances functional recovery and up-regulates the expression of a molecular marker of neuronal sprouting following focal cerebral infarction. Proc. Nati Acad. Sci. (1997) 94:8179–8184.
  • PAPADOPOULOS CM, TSAI S-Y, ALSBIEI T et al.: Functional recovery and neuroanatomical plasticity following middle cerebral artery occlusion and IN-1 antibody treatment in the adult rat. Ann. Neurol. (2002) 51:433–441.
  • •Demonstration of promotion of plasticity and functional recovery in a rat model of stroke following blockade of a myelin-associated inhibitory protein.
  • VERSTRAETE M: Third-generation thrombolytic drugs. Am. I Med. (2000) 109:52–58.
  • •Review of emerging thrombolytic agents.
  • PANNELL R, GUREWICH V: Pro-urokinase: a study of its stability in plasma and of a mechanism for its selective fibrinolytic effect. Blood (1986) 44:217–228.
  • SCHELLINGER PD, FIEBACH JB, MOHR A, RINGLEB PA, JANSEN O, HACKE W: Thrombolytic therapy for ischemic stroke - a review. Part II - intra-arterial thromolysis, vertebrobasilar stroke, Phase IV trials, and stroke imaging. Crit. Care Med. (2001) 29:1819–1825.
  • •Comprehensive review of clinical trials of intra-arterial thrombolysis.
  • HENNERICI MG, BOGOUSSLAVSKYJ, LENZI GL, ORGOGOZO GM: European stroke treatment with Ancrod trial (ESTAT) - initial results. Neurosci. (2001) 187\(Suppl. 1):S436.
  • TOOMEY JR, VALOCIK RE, KOSTER PF et al.: Inhibition of Factor IX(a) is protective in a rat model of thromboembolic stroke. Stroke (2002) 33:578–585.
  • NURDEN AT, POUJOL C, DURRIEU-JAIS C, NURDEN P: Platelet glycoprotein IIb/IIIa inhibitors. Basic and clinical aspects. Arteriosclec Thromb. Vasc. Biol. (1999) 19:2835–2840.
  • ADAMS HP, BOGOUSSLAVSKY J, BARNATHAN E et al: Abciximab in acute ischemic stroke. Stroke (2000) 31:601–609.
  • LEE DH, JO KD, KIM HG et al: Local intraarterial urokinase thrombolysis of acute ischemic stroke with or without intravenous abciximab: a pilot study.' Vasc. Intervent. Radial. (2002) 13:769–773.
  • VOLPE M, COSENTINO F: Abnormalities of endothelial function in the pathogenesis of stroke: the importance of endothelin.J. Cardiovasc. Pharmacol. (2000) 35 (Suppl. 2):545–548.
  • PATEL TR, GALBRAITH S, GRAHAM DI et al.: Endothelin receptor antagonist increases cerebral perfusion and reduces ischaemic damage in feline focal cerebral ischaemia.f Cereb. Blood Flow Metab. (1996) 16:950–958.
  • DAWSON DA, SUGANO H, MCCARRON RM, HALLENBECK JM, SPATZ M: Endothelin receptor antagonist preserves microvascular perfusion and reduced ischaemic brain damage following permanent focal ischaemia. Neurochem. Res. (1999) 24:1499–1505.
  • MATSUO Y, MIHARA S-I, MITSUYOSHI N, FUJIMOTO M: Protective effect of endothelin type A receptor antagonist on brain oedema and injury after transient middle cerebral artery occlusion in rats. Stroke (2001) 32:2143–2148.
  • BARONE FC, OHLSTEIN EH, HUNTER Al et al.: Selective antagonism of endothelin-A receptors improves outcome in both head trauma and focal stroke in rat. Cardiovasc. Pharmacol (2000) 36\(Suppl. 1):5357–5361.
  • FINKLESTEIN SP, FISHER M, FURLAN AJ et al: Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke (1999) 30:2752–2758.
  • ••Reviews preclinical reasons for failed stroketrials and makes recommendations for optimal preclinical development of stroke drugs.
  • ALBERS GW, BOGOUSSLAVSKY J, BOZIK MA et al.: Recommendations for clinical trial evaluation of acute stroke therapies. Stroke (2001) 32:1598–1606.
  • ••Reviews clinical reasons for failed stroke trials and makes recommendations for optimal clinical development of stroke drugs.
  • IKONOMIDOU C, TURSKI L: Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury? Lancet Neurol (2002) 1:383–386.
  • •Hypothesis for failure of NMDA antagonists in clinical trials.
  • ZANETTE EM, ROBERTI C, MANCINI G, POZZILLI C, BRAGONI M, TONI D: Spontaneous middle cerebral artery reperfusion in ischemic stroke: a follow-up study with transcranial doppler. Stroke (1995) 26:430–433.
  • PARSONS CG, DANYSZ W, QUACK G: Memantine is a clinically well tolerated N-metyld-D-aspartate (NMDA) receptor antagonist - a review of preclinical data. Neuropharmacol. (1999) 38:735–767.
  • TAKAHASHI M, NI JW, KAWASAKI-YATSUGI S et al: YM872, a novel selective a-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist, reduced brain damage after permanent focal cerebral ischemia in cats. Pharm. Exp. Therap. (1998) 284:467–473.
  • SHIMIZU-SASAMATA M, KANO T, ROGOWSKA J, WOLF G, MOSKOWITZ MA, LO EH: YM872, a highly water-soluble AMPA antagonist, preserved the hemodynamic penumbra and reduces brain injury after permanent focal ischemia in rats. Stroke (1998) 29:2141–2148.
  • NIELSEN EO, VARMING T, MATHIESEN C et al: SPD 502: a water-soluble and in vivo long-lasting AMPA antagonist with neuroprotective activity. Pharmacol Exp. Therap. (1999) 289:1492–1501.
  • NAPOLIELLO MJ, DE VOSS RW: Clinical experience with YM872, a novel AMPA receptor antagonist for acute ischemic stroke. Stroke (1999) 30:264.
  • SANG CN, HOSTETTER MP, GRACELY RH et al.: AMPA/kainate antagonist LY293558 reduces capsaicin-evoked hyperalgesia but not pain in normal skin in humans. Anesthesiology (1998) 89:1060–1067.
  • DI X, BULLOCK R, WATSON J et al.: Effect of CP101,606, a novel NR2B subunit antagonist of the N-methyl-D-aspartate receptor, on the volume of ischemic brain damage and cytotoxic brain edema after middle cerebral artery occlusion in the feline brain. Stroke (1997) 28:2244–2251.
  • MERCHANT R, BULLOCK MR, CARMACK CA et al.: A double-blind, placebo-controled study of the safety, tolerability and pharmacokinetics of CP-101,606 in patients with a mild or moderate traumatic brain injury. Ann. NY Acad. Sci. (1999) 890:42–50.
  • BULLOCK MR, MERCHANT RE, CARMACK CA et al.: An open-label study of CP-101,606 in subjects with a severe traumatic head injury or spontaneous intracerebral hemorrhage. Ann. NY Acad. Sci. (1999) 890:51–58.
  • MARINOV MB, HARBAUGH KS, HOOPES PJ, PIKUS HJ, HARBAUGH RE: Neuroprotective effects of preischemia intraarterial magnesium sulfate in reversible focal cerebral ischemia. J.Neurosurg. (1996) 85:117–124.
  • IZUMI Y, ROUSSEL S, PINARD E, SEYLAZ J: Reduction of infarct volume by magnesium after middle cerebral artery occlusion in rats../. Cereb. Blood Dow Metab. (1991) 11:1025–1030.
  • HARRISON NL, SIMMONDS MA: Quantitative studies on some antagonists of N-methyl D-aspartate in slices of rat cerebral cortex. Br. J. Pharmacol (1985) 84:381–368.
  • MUIR KW, LEES KR: Dose optimisation of intravenous magnesium sulfate after acute stroke. Stroke (1998) 29:918–923.
  • BRADFORD A, LEES K: Design of the intravenous magnesium efficacy in acute stroke (IMAGES) trial. Carr: Control Trials Cardiovasc. Med. (2000) 1:184–190.
  • SHOHAMI E, MECHOULAM R: Dexanabimol (HU-211): a nonpsychotropic cannabinoid with neuroprotective properties. Drug Develop. Res. (2000) 50:211–215.
  • LAVIE G, TEICHNER A, SHOHAMI E, OVADIA H, LEKER RR: Long term cerebroprotective effects of dexanabinol in a model of focal cerebral ischemia. Brazil Res. (2001) 901:195–201.
  • KNOLLER N, LEVI L, SHOSHAN I et al.: Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, Phase II clinical trial. Crit. Care Med. (2002) 30:548–554.
  • ANGEL I, KRAKOVSKY M, SHEMESH T, BEIT-YANNAI E, FRIEDMAN JE, KOZAK: DP-699 a neuroprotective agent for cerebral ischemia. Biochem. Int. (2000) Nov/Dec:20–22.
  • CARTER AJ, GRAUERT M, PSCHORN U et al: Potent blockade of sodium channels and protection of brain tissue from ischemia by Bill 890CL. Proc. Natl. Acad. Sci. (2000) 97:4944–4949.
  • WEISER T, BRENNER M, PALLUK R et al: BIIR 561 CL: A novel combined antagonist of a-amino-3-hydroxy-5-methy1-4-isoxazolepropionic acid receptors and voltage-dependent sodium channels with anticonvulsive and neuroprotective properties. I Pharmacol Exp. Therap. (1999) 289:1343–1349.
  • YENARI MA, PALMER JT, HUA SUN G et al.: Time-course and treatment response with SNX-111, an N-type calcium channel blocker, in a rodent model of focal cerebral ischemia using diffusion-weighted MRI. Brain Res. (1996) 739:36–45.
  • BOWERSOX SS, SINGH T, LUTHER RR: Selective blockade of N-type voltage-sensitive calcium channels protects against brain injury after transient focal cerebral ischemia in rats. Brazil Res. (1997) 747:343–347.
  • HICKS CA, WARD MA, O'NEILL MJ: Neuroprotective effects of the neuronal Ca2+ channel blockers, LY042826 and LY393615 in vivo. Eur. Pharmacol (2000) 408:241–248.
  • AOKI Y, TAMURA M, ITOH Y, UKAI Y et al.: Cerebroprotective action of a Nei Ca2+ channel blocker NS-7 I. Effect on the cerebral infarction and edema at the acute stage of permanent middle cerebral artery occlusion in rats. Brain Res. (2001) 890:162–169.
  • TAMURA M, AOKI Y, SETO T, ITOH Y, UKAI Y: Cerebroprotective action of a Nei Ca2+ channel blocker NS-7 II. Effect on the cerebral infarction, behavioural and cognitive impairments at the chronic stage of permanent middle cerebral artery occlusion in rats. Brain Res. (2001) 890:170–176.
  • MAULER F, MITTENDORF J, HORVATH E et al.: Characterization of the diarylether sulfonylester ( )-R-3- (2 hydroxymethylindany1-4-oxy)pheny1-4,4,4-trifluoro-1-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties. J. Pharmacol Exp. Therap. (2002) 302:359–368.
  • PIOMELLI D, GIUFFRIDA A, CALIGNANO A, DE FONSECA FR: The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol Sci. (2000) 21:218–224.
  • CHAN P: Reactive oxygen radicals in signaling and damage in the ischemic brain. Cereb. Blood Flow Metab. (2001) 21:2–14.
  • MCCULLOCH J, DEWAR D: A radical approach to stroke therapy. Proc. Natl. Acad. Sci. (2001) 98:10989–10991.
  • TABRIZCHI R: Edaravone. Carr. Opin. Invest. Drugs (2000) 1:347–354.
  • JIN Y-J, MIMA T, RAICU V, PARK KC, SHIMIZU K: Combined argatroban and edaravone caused additive neuroprotection against 15 min of forebrain ischemia in gerbils. Neurosci. Res. (2002) 43:75–79.
  • MULLER A, CADENAS E, GRAF P, SIES H: A novel biologically active selenoorganic compound-I. Glutathione perwddase-like activity in vitro and antioxidant capacity of PZ51 (ebselen). Biochem. Pharmacol (1984) 33:3235–3239.
  • IMAI H, MASAYASU H, DEWAR D, GRAHAM DI, MACRAE IM: Ebselen protects both gray and white matter in a rodent model of focal cerebral ischemia. Stroke (2001) 32:2149–2154.
  • YAMAGUCHI T, SANO K, TAKAKURA K et al.: Ebselen in acute ischemic stroke. Stroke (1998) 29:12–17.
  • OGAWA A, YOSHIMOTOT, KIKUCHI H et al.: Ebselen in acute middle cerebral artery occlusion: a placebo-controlled, double-blind clinical trial. Cerebrovasc. Dis. (1999) 9:112–118.
  • •Clinical trial showing efficacy of ebselen in acute stroke.
  • MACLENNAN KM, DARLINGTON CL, SMITH PF: The CNS effects of Ginkgo biloba extracts and ginkgolide B. Frog. Neurobiol (2002) 67:235–257.
  • SYDSERFF SG, BORELLI AR, GREEN AR, CROSS AJ: Effect of NXY-059 on infarct volume after transient or permanent middle cerebral artery occlusion in the rat; studies on dose, plasma concentration and therapeutic time window. Br. J. Pharmacol (2002) 135:103–112.
  • MARSHALL JWB, DUFFIN KJ, GREEN AR et al: NXY-059, a free radical trapping agent, substantially lessens the functional disability resulting from cerebral ischaemia in a primate species. Stroke (2001) 32:190–198.
  • LEES KR, SHARMA AK, BARER D et al.: Tolerability and pharmacokinetics of the nitrone NXY-059 in patients with acute stroke. Stroke (2001) 32:675–680.
  • TATEISHI N, MORI T, KAGAMIISHI Y et al.: Astrocytic activation and delayed infarct expansion after permanent focal ischemia in rats. Part II: suppression of astrocytic activation by a novel agent (R) ( ) 2 propyloctanoic acid (ONO-2506) leads to mitigation of delayed infarct expansion and early improvement of neurologic deficits. I Cereb. Blood Dow Metab. (2002) 22:723–734.
  • STACPOOLE PW: The pharmacology ofdichloroacetate. Metabolism (1989) 38:1124–1144.
  • GRAHAM GD, KALVACH P, BLAMIRE AM, BRASS LM, FAYAD PB, PRICHARD JW: Clinical correlates of proton magnetic resonance spectroscopy findings after acute cerebral infarction. Stroke (1995) 26:225–229.
  • PEELING J, SUTHERLAND G, BROWN RA, CURRY S: Protective effect of dichloroacetate in a rat model of forebrain ischemia. Neurosci. Lett. (1996) 208:21–24.
  • GRAHAM GD, BARLER PB, BROOKS WM et al.: MR spectroscopy study of dichloroacetate treatment after ischemic stroke. Neurology (2000) 55:1376–1378.
  • TARNOPOLSKY MA, BEAL MF: Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders. Ann. Neurol (2001) 49:561–574.
  • HEFTI F: Pharmacology of neurotrophicfactors. Ann. Rev Pharmacol Toxicol (1997) 37:239–267.
  • •Overview of predinical and clinical data for neurotrophic factors in peripheral and CNS diseases.
  • BOGOUSSLAVSKY J, VICTOR SJ, SALINAS EO et al: Fiblast (trafermin) in acute stroke: results of the European-Australine Phase II/III safety and efficacy trial. Cerebrovasc. Dis. (2002) 14:239–251.
  • SEMKOVA I, KRIEGLSTEIN J: Neuroprotection mediated via neurotrophic factors and induction of neurotrophic factors. Brain Res. Rev. (1999) 30:176–188.
  • TATSUNO I, MORIO H, TANAKA T et al.: Pituitary adenylate cyclase-activating polypeptide (PACAP) is a regulator of astrocytes: PACAP stimulates proliferation and production of inter-leukin 6 (IL-6), but not nerve growth factor (NGF), in cultured rat astrocyte. Ann. NYAcad. Li. (1996) 805:482–488.
  • REGLODI D, SOMOGYVARI-VIGH A, VIGH S et al.: Delayed systemic administration of PACAP38 is neuroprotective in transient middle cerebral artery occlusion in the rat. Stroke (2000) 31:1411–1417.
  • DAGO L, BONDE C, PETERS D et al: NS 1231, a novel compound with neurotrophic-like effects in vitro and in vivo. Neurochem. (2002) 81:17–24.
  • SEMKOVA I, WOLZ P, KRIEGLSTEIN J: Neuroprotective effect of 5-HT1A receptor agonist, Bayx3702, demonstrated in vitro and in vivo. Eur.j Pharmacol (1998) 359:251–260.
  • KAMEI K, MAEDA N, OGINO R et al: New 5-HTiAreceptor agonists possessing 1,4-benzoxazepine scaffold exhibit highly potent anti-ischemic effects. Bioorg. Med. Chem. Lett. (2001) 11:595–598.
  • WHITAKER-AZMITIA PM, DRUSE M, WALKER P, LAUDER JM: Serotonin as a developmental signal. Behav. Brain Res. (1996) 73:19–29.
  • TEAL P, SILVER F, GROTTA J, SIMARD D: The neuroprotectant BAY X 3702 in acute ischemic stroke: BRAINS. Neurology (1999) 52\(Suppl. 2):A383–A384.
  • TEAL P, ROMBOUT F, WEBER H et al: Repinotan: an innovative Phase III design in stroke. Stroke (2001) 31:2811.
  • PHILLIPS JB, WILLIAMS AJ, ADAMS J, ELLIOTT PJ, TORTELLA FC: Proteasome inhibitor PS519 reduces infarction and attenuates leukocyte infiltration in a rat model of focal cerebral ischemia. Stroke (2000) 31:1686–1693.
  • LODDICK SA, WONG M-L, BONGIORNO PB et al: Endogenous interleukin-1 receptor antagonist is neuroprotective. Ear: .1.Pharmacol (1997) 234:211–215.
  • BARONE FC, ARVIN B, WHITE RF et al.: Tumor necrosis factor-a. A mediator of focal ischemic brain injury. Stroke (1997) 28:1233–1244.
  • HERLAAR E, BROWN Z: p38 MAPK signalling cascades in inflammatory disease. Ma Med. Today(1999) 5: 439–447.
  • LEGOS JL, ERHARDT JA, WHITE RF et al.: SB 239063, a novel p38 inhibitor, attenuates early neuronal injury following ischemia. Brain Res. (2001) 892:70–77.
  • CHONG ZZ, KANG J-Q, MAIESE K: Hematopoietic factor erythropoietin fosters neuroprotection through novel signal transduction cascades.' Cereb. Blood Flow Metab. (2002) 22:503–514.
  • BRINES ML, GHEZZI P, KEENAN S et al.: Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc. Natl. Acad. Sci. (2000) 97:10526–10531.
  • EHRENREICH H, HASSELBLATT M, DEMBOWSKI C et al.: Erythropoietin therapy for acute stroke is both safe and beneficial. MM. Med. (2002) 8:495–505.
  • WIESSNER C, ALLEGRINI PR, EKATODRAMIS D et al.: Increased cerebral infarct volumes in polyglobulic mice overexpressing erythropoietin. Cereb. Blood Flow Metab. (2001) 21:857–864.
  • CASADEVALL N, NATAF J, VIRON B et al.: Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl. I Med. (2002) 346:469–475.
  • MORRIS DC, ZHANG L, ZHANG ZG et al.: Extension of the therapeutic window for recombinant tissue plasminogen activator with argatroban in a rat model of embolic stroke. Stroke (2001) 32:2635–2640.
  • SCHABITZ WR, FUHAI L, IRIE K et al: Synergistic effects of a combination of low-dose basic fibroblast growth factor and citicoline after temporary experimental focal ischemia. Stroke (1999) 30:427–432.
  • ONAL MZ, FUHAI L, TATLISUMAK T et al.: Synergistic effects of citicoline and MK-801 in temporary experimental ischemia in rats. Stroke (1997) 28:1060–1065.
  • PRATT RD, PERDOMO CA: Results of clinical studies with donepezil in vascular dementia. Am. I Geriatr. Psych. (2002) 10(Suppl.):S34–S41.
  • MORETTI R, TORRE P, ANTONELLO RM et al.: An open-label pilot study comparing rivastigmine and low-dose aspirin for the treatment of symptoms specific to patients with subcortical vascular dementia. Curr: Therap. Res. (2002) 63:443–458.
  • BULLOCK R, LILLENFELD S: Galantamine shows promising results in Alzheimer's disease with cerebrovascular components and probable vascular dementia (preliminary results). I Neurosci. (2001) 187\(Suppl. 1)559.
  • ENDERBY P, BROECKXJ, HOSPERS W, SCHILDERMANS F, DEBERDT W: Effect of piracetam on recovery and rehabilitation after stroke: a double-blind, placebo-controlled study. Clin. Neuropharmacol (1994) 17:320–331.
  • KESSLER J, THIEL A, KARBE H, HEISS WD: Piracetam improves activated blood flow and facilitates rehabilitation of poststroke aphasic patients. Stroke (2000) 31:2112–2116.
  • ORGOGOZO JM: Piracetam in the treatment of acute stroke. CNS Drugs (1998) 9\(Suppl. 1):41–49.
  • GLADSTONE DJ, BLACK SE: Enhancing recovery after stroke with noradrenergic pharmacotherapy: a new frontier? Can. Nemo. ScL (2000) 27:97–105.
  • •Review of animal and clinical trials of the ability of amphetamine to promote stroke recovery.
  • GOLDSTEIN LB: Effects of amphetamines and small related molecules on recovery after stroke in animals and man. Neuropharmacol (2000) 39:852–859.
  • •Review of effects of drugs which modulate levels of central neurotransmitters on functional recovery in animal models of focal brain injury.
  • STROEMER RP, KENT TA, HULSEBOSCH CE: Enhanced neocortical neural sprouting, synaptogenesis, and behavioural recovery with D-amphetamine therapy after neocortical infarction in rats. Stroke (1998) 29:2381–2395.
  • •Demonstration of the ability of amphetamine to promote plasticity and functional recovery in a rat model of stroke.
  • CRISOSTOMO EA, DUNCAN PW, PROPST M, DAWSON DV, DAVIS JN: Evidence that amphetamine with physical therapy promotes recovery of motor function in stroke patients. Ann. Neurol (1988) 23:94–97.
  • WALKER-BATSON D, SMITH P, CURTIS S, UNWIN H, GREENLESS R: Amphetamine paired with physical therapy accelerates motor recovery after stroke. Smoke (1995) 26:2254–2259.
  • MAZAGRI R, SHUAIB A, MCPHERSON M, DEIGHTON M: Amphetamine failed to improve motor function in acute stroke.' Can. Sci. _NPurol. (1995) 22:S25.
  • REDING M, SOLOMOM B, BORUCKI S: Effect of dextroamphetamine on motor recovery after stroke. Neurology (1995) 45\(Suppl. 4):S01.
  • SONDE L, NORDSTROM M, NILSSON C-G, LOKK J, VIITANEN M: A double-blind placebo-controlled study of the effects of amphetamine and physiotherapy after stroke. Cerebrovasc. Dis. (2001) 12:253–257.
  • DAM M, TONIN P, DEBONI A et al: Effects of fluoxetine and maprotiline on functional recovery in poststroke haemiplegic patients undergoing rehabilitation therapy. Stroke (1996) 27:1211–1214.
  • GRADE C, REDFORD B, CHROSTOWSKIJ et al: Methylphenidate in early poststroke recovery: a double-blind, placebo-controlled study. Arch. Phys. Med. Rehabil (1998) 79:1047–1050.
  • SCHEIDTMANN K, FRIES W, MULLER F, KOENIG E: Effect of levodopa in combination with physiotherapy on functional motor recovery after stroke: a prospective, randomised, double-blind study. Lancet (2001) 358:787–790.
  • SEIL Fl: Recovery and repair issues after stroke from the scientific perspective. Curt-. Opin. Neurol (1997) 10:49–51.
  • KAWAMATA T, ALEXIS AE, DIETRICH D, FINKLESTEIN SP: Intracisternal basic fibroblast growth factor (bFGF) enhances behavioural recovery following focal cerebral infarction in the rat. Cereb. Blood Dow Metab. (1996) 16:542–547.
  • KAWAMATA T, REN JM, CHAN TCK, CHARETTE M, FINKLESTEIN SP: Intracisternal osteogenic protein-1 enhances functional recovery following focal stroke. Neuroreport (1998) 9:1441–1445.
  • JIN K, ZHU Y, SUN Y, OU MAO X, XIE P, GREENBERG DA: Vascular endothelial growth factor (VEGF) stimulates neurogenesis M vitro and in vivo. Proc. Natl. Acad. Sci. (2002) 99:11946–11950.
  • ZHANG ZG, ZHANG L, JIANG Q et al: VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. Gin. Invest. (2000) 106:829–838.
  • FOURNIER A, STRITTMATTER SM: Repulsive factors and axon regeneration in the CNS. CLIFF. Opin. Neurobiol (2001) 11: 89–94.
  • ••Review of factors which inhibit axonalregeneration in CNS.
  • WANG KC, KOPRIVICA V, SIVASANKARAN R et al.: Oligodendrocyte-myelin glycoprotein is a Nogo receptor ligand that inhibits neurite outgrowth. Nature (2002) 417:941–944.
  • FOURNIER AE, GRANDPRE T, STRITTMATTER SM et al.: Identification of a receptor mediating Nogo-66 inhibition of axonal regeneration. Nature (2001) 409:341–346.
  • DOMENICONI M, CAO Z, SPENCER T et al.: Myelin-associated glycoprotein interacts with the Nogo66 receptor to inhibit neurite outgrowth. Neuron (2002) 35:283–290.
  • GRANDPRE T, LI S, STRITTMATTER SM: Nogo-66 receptor antagonist peptide promotes axonal regeneration. Nature (2002) 417:547–551.
  • YAMASHITA T, HIGUCHI H, TOHYAMA M: The p75 receptor transduces the signal from myelin-associated glycoprotein to Rho.' Cell Biol. (2002) 157:565–570.
  • VINSON M, STRIJBOS PJLM, ROWLES A et al.: Myelin-associated glycoprotein interacts with ganglioside GT113.J. Biol. Chem. (2001) 276:20280–20285.
  • SONG H-J, POO M-M: Signal transduction underlying growth cone guidance by diffusible factors. Can: Opin. Neurobiol (1999) 9:355–363.
  • PASTERKAMP RJ, VERHAAGEN J: Emerging roles for semaphorins in neural regeneration. Brain Res. Rev. (2001) 35:36–54.
  • HALL A: Rho GTPases and the actin cytoskeleton. Science (1998) 279:509–514.
  • YAMASHITA T, TUCKER KL, BARDE YA: Neurotrophin binding to the p75 receptor modulates Rho activity and axonal outgrowth. Neuron (1999) 24:585–593.
  • NEUMANN H, SCHWEIGREITER R, YAMASHITA T et al.: Tumor necrosis factor inhibits neurite outgrowth and branching of hippocampal neurons by a Rho-dependent mechanism. J. Neurosci. (2002) 22:854–862.
  • JIN Z, STRITTMATTER SM: Racl mediates collapsin- 1 -induced growth conecollapse. 1 Neurosci. (1997) 17:6256–6263.
  • LEHMANN M, FOURNIER A, SELLES-NAVARRO et al.: Inactivation of Rho signalling pathway promotes CNS axon regeneration. J. Neurosci. (1999) 19:7537–7547.
  • DERGHAM P, ELLEZAM B, ESSAGIAN C et al.: Rho signalling pathway targeted to promote spinal cord repair. J. Neurosci. (2002) 22:6570–6577.
  • SCHNELL L, SCHNEIDER R, KILBECK R et al: Neurotrophin-3 enhances sprouting of corticospinal tract during development and after adult spinal cord lesion. Nature (1994) 367:170–173.
  • NO AUTHORS LISTED: Major on-going stroke trials Stroke (2002) 33:2525–2535.
  • •Listing of current major stroke trials. Updated quarterly.
  • HANKEY GJ, EIKELBOOM JW: Homocysteine and stroke. Can: Opin. Neurol (2001) 14:95–102.
  • SPENCE JD, HOWARD VJ, CHAMBLESS LE et al.: Vitamin intervention for stroke prevention WISP) trial: rationale and design. Neuroepidemiology (2001) 20:16–25.
  • BAKER RI, EIKELBOOM J, GELAVIS A et al.: The VITATOPS (vitamins to prevent stroke) Trial: rationale and design of an international, large, simple, randomised trial of homocysteine-lowering multivitamin therapy in patients with recent transient ischaemic attack or stroke. Cerebrovasc. Drs. (2002) 13:120–126.
  • DONNAN GA, DAVIS SM: Neuroimaging, the ischaemic penumbra, and selection of patients for acute stroke therapy. Lancet Neurol (2002) 1:417–425.
  • WU DF, SONG BW, VINTERS HV, PARDRIDGE WM: Pharmacokinetics and brain uptake of biotinylated basic fibroblast growth factor conjugated to a blood-brain barrier drug delivery system. J. Drug Targeting (2002) 10:239–245.
  • DAVIS SM, LEES KR, ALBERS GW et al: Selfotel in acute ischemic stroke: possible neurotoxic effects of an NMDA antagonist. Stroke (2000) 31:347–354.
  • ALBERS GV, GOLDSTEIN LB, HALL D, LESKO LM: Aptiganel hydrochloride in acute ischemic stroke - a randomized controlled trial. JAMA (2001) 286:2673–2682.
  • LEES KR: Cerestat and other NMDA antagonists in ischemic stroke. Neurology (1997) 49:S66–S69.
  • ALBERS GW, CLARK WM, ATKINSON RP et al: Dose escalation study of the NMDA glycine-site antagonist licostinel in acute ischemic stroke. Stroke (1999) 30:508–513.
  • SACCO RL, DEROSA JT, HALEY EC et al.: Glycine antagonist in neuroprotection for patients with acute stroke - GAIN Americas: a randomized controlled trial. JA/VIA (2001) 285:1719–1728.
  • MOHR JP, ORGOGOZO JM, HARRISON MJG et al.: Meta-analysis of oral nimodipine trials in acute ischemic stoke. Cerebrovasc Dis. (1994) 4:197–203.
  • HORN J, DE HAAN RJ, VERMEULEN M, LIMBURG M: Very early nimodipine use in stroke (VENUS). A randomized, double-blind, placebo-controlled trial. Stroke (2001) 32:461–465.
  • BATH PMW, IDDENDEN R, BATH FJ, ORGOGOZO JM: Tirilazad mesylate in acute ischemic stroke: a systematic review. Stroke (2000) 31:2257–2265.
  • DIENER HC, CORTENS M, FORD G et al.: Lubeluzole in acute ischemic stroke treatment. A double-blind study with an 8-hour inclusion window comparing a 10-mg daily dose of lubeluzole with placebo. Stroke (2000) 31:2543–2551.
  • WAHLGREN NG, RANASINHA KW, ROSOLACCI T et al.: Results of a randomized, controlled trial of clomethiazole versus placebo in 1360 acute stroke patients. Stroke (1999) 30:21–28.
  • CLARK WM, RAPS EC, TONG DC, KELLY RE: Cervene (Nalmefene) in acute ischemic stroke: final results of a Phase III efficacy study. The Cervene stroke study investigators. Stroke (2000) 31:1234–1239.
  • CLARK WM, WARACH SJ, PETTIGREW LC et al.: A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology (1997) 49:671–678.
  • CLARK WM, WARACH SJ, PETTIGREW LC et al.: A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke (1999) 30:2592–2597.
  • CLARK WM, WECHSLER LR, SABOUNJIAN LA, SCHVVIDERSKI UE: A Phase III randomized efficacy trial of 2000mg citicoline in acute ischemic stroke patients. Neurology (2001) 57:1595–1602.
  • SHERMAN DG, BEW A, EASTON JD et al.: Use of anti-ICAM-1 therapy in ischemic stroke. Neurology(2001) 57: 1428–1440.

Websites

  • http://www.scripdaily.com Scrip Daily Online, 9 Jul 2002.Subscribers only.
  • http://www.scripdaily.com Scrip Daily Online, 30 Oct 2002.Subscribers only.
  • http://www.strokecentres.org Internet Stroke Centre Stroke trials directory.
  • http://www.tbc.com Texas Biotechnology, press release, 2 Oct 2002.
  • http://www.tbc.com Texas Biotechnology, press release, 17 Sep 2002.
  • http://www.neurosearch.com Annual Report, NeuroSearch, 2000.
  • http://www.shire.com Annual Report, Shire, 2001.
  • http://www.ims-global.com/products/ lifecycle/r_and_d.htm IMS Lifecycle - R&D focus
  • http://www.scripdaily.com Scrip Daily Online, 7 Jun 2001.Subscribers only.
  • http://www.mlnm.com/ Millennium company web-page.
  • http://www.mlnm.com/media/news Press release, Millennium, 14 March 2002.
  • http://www.basp.ac.uldemsleysmithwith.htm British Association of Stroke physicians website.
  • http://www.vpharm.com/ Vertex company web page.
  • http://www.bms.com/news/data/ presar.html Press release, Bristol-Myers-Squibb, press release, 24 Jan 2001.
  • http://www.astrazeneca.com Press release, AstraZeneca 15 Nov 2000.
  • http://www.icos.com/news/index.html Press releases, ICOS, 25 Jan 1999 and 20 Apr 2000.
  • http://www.corvas.com/ company_body.html Press release, Corvas, 14 Jun 2002.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.